University of California, San Diego
Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk. There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant, etc.) who are taking five or more medications in which drug-drug interactions may prevent optimization of statin therapy.
This is an investigator-initiated, single-site, open-label, randomized trial. The investigators will enroll up to 100 high-risk primary prevention patients with at least one comorbidity and an indication for additional lipid control (such as Type II diabetes with A1c ≤ 8.5%, subclinical atherosclerosis, or increased 10-year ASCVD risk). Patients will be randomized 1:1 to the inclisiran arm (n ≥ 50) with standard of care or standard of care alone (n ≥ 50). The study will consist of five study visits (screening, baseline, 3 months, 9 months, and 12 months). Patients in the inclisiran arm will r…
Inclusion Criteria: To be eligible to participate in this study, individuals must meet all of the following criteria: 1. Provide signed and dated informed consent form. 2. Are willing to comply with all study procedures and availability for the duration of the study including the potential randomization to injections, as stated by the participant and assessed by study staff. 3. Are ≥ 18 and ≤ 85 years of age with the ability to consent for themselves. 4. Take 5 or more medications at the time of enrollment (any type of medication). This includes prescription drugs, as well as over-the-counte…
The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 month and 9 month visit.